Women age 16-45 who are pregnant or who have just delivered will be eligible to participate in a study involving the 9-valent HPV vaccine. For clarification, women who are pregnant are eligible to sign consent, but the first vaccine will not occur until after delivery. Vaccine # 1 must occur within seven days of delivery.~The main objective of the study is to determine the immunogenicity of the vaccine in postpartum women. The immunogenicity results will be compared to that of non-postpartum women of the same age, 16-45.~Women will participate for approximately 12 months and will complete a total of 4 visits during that time frame.
This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.